SLC50A1 is a sugar transporter belonging to the SWEET (Sugars Will Eventually be Exported Transporters) family, the sole human member of the SLC50 glucose uniporter class 1. It mediates sugar transport across cellular membranes, particularly glucose and glucose-like molecules 1. SLC50A1 was originally identified as a stromal cell-derived protein facilitating RAG-1 gene activation in lymphoid progenitors, suggesting a role in V(D)J recombination 2. Genetically, SLC50A1 variants are associated with glucose metabolism and 1,5-anhydroglucitol (1,5-AG) concentrations, a biomarker of hyperglycemic excursions 3. A homozygous missense variant (c.245T>C; p.Leu82Pro) in SLC50A1 was identified in a Pakistani family with severe non-syndromic intellectual disability, suggesting potential roles in cognitive function 4. Clinically, SLC50A1 shows relevance to cancer biology: serum SLC50A1 levels discriminate breast cancer patients from healthy controls (sensitivity 75.3%, specificity 100%) and associate with unfavorable prognosis in high-grade breast cancer (HR=1.823, P=0.01) 5. Additionally, SLC50A1 is involved in synthetic lethal interactions with ABL1 in cancer cells 6, and alternative splicing of SLC50A1 relates to histone deacetylase inhibitor resistance in cutaneous T-cell lymphomas 7.